The majority of the L-DOS47 expenditures through the quarter were associated with the scale-up manufacturing of GMP engineering batches in preparation for clinical trial batch manufacturing.
The majority of the Topical Interferon Alpha-2b expenditure increase through the quarter reflects the ongoing costs of the AGW Phase II clinical trial in Sweden and Germany in addition to the costs of the ongoing Phase II pharmacokinetic study and the scale-up manufacturing efforts associated with the LSIL therapeutic indication program.
Operating, general & administration
Operating, general & administration expenses totaled $1,231,000 and $3,854,000 respectively for the three and nine month periods ended April 30, 2009 (three and nine month periods ended April 30, 2008: $1,060,000 and $3,618,000 respectively).
Operating, general and administration expenses were higher for both the three and nine month periods ended April 30, 2009 and mainly reflect the higher one time costs associated with the filing of a Form 20-F registration statement with the U.S. Securities and Exchange Commission, which became effective during the third quarter of fiscal 2009. Also, increased expenditures are associated with the implementation of a new financial reporting system and capital raising initiatives. Offsetting some of the aforementioned increases in expenditures are lower wages and benefits from the foregoing of accrued vacation days by management during the current fiscal year and lower wages and benefits due to a one-time charge relating to the resignation of the Company's Chairman, and management bonuses paid, in the nine month period ended April 30, 2008.
Amortization of c
|SOURCE Helix BioPharma Corp.|
Copyright©2009 PR Newswire.
All rights reserved